FOLH1 and prostate carcinoma: Targeted radioligand therapy (TRT) is a selective or specific administration of a high dose of radiotoxicity to cancer cells without destroying the surrounding healthy cells.23,24 It typically employs targeting vectors such as proteins, peptides, carbohydrates, vitamins, antibodies, and aptamers.25 Metal-based small-molecule PSMA radioligands have shown a growing interest in TRT prostate cancer.26 A common strategy to develop PSMA-specific based radiometal ligands is shown in Figure 1.